Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3.
doi: 10.1097/PAI.0000000000001281. Online ahead of print.

Interobserver and Interassay Concordance in HER2 Immunohistochemistry: Implications on HER2-Low Breast Cancer

Ozgur Can Eren  1 , Orhun Cig Taskin  1 , Murat Oktay  2 , Arzu Baygul  3 , Fatma Aktepe  2 , Nilgun Kapucuoglu  1
Affiliations

Interobserver and Interassay Concordance in HER2 Immunohistochemistry: Implications on HER2-Low Breast Cancer

Ozgur Can Eren et al. Appl Immunohistochem Mol Morphol. .

Abstract

Adopting a HER2-specific treatment approach for HER2-low breast cancer has been suggested after DESTINY-Breast04 (phase 3) trials. Hence, accurate pathologic evaluation gained higher importance, making interobserver agreement and interassay agreement questionable in this regard. To evaluate these, a cohort of 116 invasive breast cancer cases were stained with Dako A0485 and Ventana 4B5. Cases were evaluated by 5 observers independently and results were compared, together with in situ hybridization findings. Interobserver agreement (Kappa) for Ventana 4B5 and Dako A0485 were 0.62 and 0.63, respectively. Agreement was more prominent for IHC 3+ cases, followed by IHC 0 cases. Comparing the assays with one another, 74 cases had the same score in Ventana 4B5 and Dako A0485, while 37 and 5 cases had higher scores in Dako A0485 and Ventana 4B5, respectively. The results of the study demonstrate that pathologists are relatively unanimous on distinguishing 3+ cases (Kappa-0.76: Ventana/0.78: Dako), but have less consistency in 1+ or 2+ cases (Kappa-0.59: Ventana/0.60: Dako). It also illustrates that the case can obtain different HER2 IHC scores with different assays being used. Therefore, it is suggested for pathologists to recognize the pitfalls in HER2 IHC, be aware of the assay that is being used in their laboratory and hence evaluate the results in the accurate context.

Keywords: HER2; HER2-low; breast carcinoma; immunohistochemistry; interobserver concordance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
    1. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–621.
    1. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20.
    1. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2023;147:993–1000.
    1. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151–1161.

LinkOut - more resources